OncoMatch/Clinical Trials/NCT05067348
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
Is NCT05067348 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tocilizumab Injectable Product for myasthenia gravis, generalized.
Treatment: Tocilizumab Injectable Product — Randomized, double-blind, placebo-controlled, parallel-group study with optional open-label extension.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage MGFA CLASS II, MGFA CLASS III, MGFA CLASS IV (MGFA)
MGFA Clinical Classification Class II, III, or IV.
Performance status
MGFA 2–4
Prior therapy
Must have received: cholinesterase inhibitor
Cholinesterase inhibitor, with no dose increase within 4 weeks prior to randomization
Must have received: corticosteroids
Corticosteroids, with no dose increase within 4 weeks prior to randomization
Must have received: non-steroidal immunosuppressive therapy (azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine A)
non-steroidal IST (including azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine A), with continuous use for at least 6 months prior to randomization and no dose increase within 4 months prior to randomization
Cannot have received: rituximab (rituximab)
Received rituximab treatment in the past 6 months before randomization
Cannot have received: IL-6 inhibitor (tocilizumab)
Received tocilizumab ... within 3 months before randomization
Cannot have received: C5 inhibitor (eculizumab)
Received ... eculizumab treatment within 3 months before randomization
Cannot have received: IVIG
Received IVIG ... within 4 weeks before randomization
Cannot have received: plasma exchange
Received ... plasma exchange within 4 weeks before randomization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify